业绩总结 - Q1 2024全球年同比营收增长5%，达到711亿美元[6] - 调整后的EBITDA在2024财年第一季度为132.0百万美元，较上年同期下降了46.2%[18] 用户数据 - 北美地区的收入在2024年3月31日至2023年4月2日的三个月内下降了25.5%，达到433.9亿美元，其中呼吸道产品的常态货币收入影响为-20.1%[15] - Point of Care部门在2024年3月31日至2023年4月2日的三个月内收入下降了39.4%，达到186.6亿美元，其中COVID-19收入影响为-76.8%[16] - 呼吸道产品的收入在2024年3月31日至2023年4月2日的三个月内下降了48.3%，达到137.3亿美元，COVID-19收入影响为-76.8%[16] - COVID-19相关政府订单对呼吸道产品收入的影响为-95.3%，达到6.7亿美元[17] 未来展望 - 去除政府COVID-19订单后，呼吸道收入同比增长6%[6] - 非呼吸道产品的收入在2024年3月31日至2023年4月2日的三个月内下降了1.2%，达到573.7亿美元，其中一次性第三方结算的影响为-100.0%[17]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-Q ____________________________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to C ...

Exhibit 99.1 May 8, 2024 QuidelOrtho Reports First Quarter 2024 Financial Results - Global year-over-year revenue growth of 5% as reported and 6% in constant currency, excluding COVID-19 revenue - - Cost reduction initiatives well underway, headcount reductions expected to deliver approximately $100 million in annualized savings - - Company suspends 2024 financial guidance while it assesses business under new President and Chief Executive Officer - First Quarter 2024 Results and Recent Highlights • Revenue ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-41409 QUIDELORTHO CORPORATION (Exact name of registrant as specified in its charter) De ...

February 13, 2024 QuidelOrtho Fourth Quarter and Full Year 2023 Financial Results © 2024. All Rights Reserved. 2 Forward-Looking Statements ...

QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2023 Earnings Conference Call February 13, 2024 5:00 PM ET Company Participants Juliet Cunningham - VP, IR Douglas Bryant - President & CEO Joseph Busky - CFO Conference Call Participants Andrew Brackmann - William Blair Alex Nowak - Craig-Hallum Casey Woodring - JPMorgan Jack Meehan - Nephron Research Conor McNamara - RBC Andrew Cooper - Raymond James Patrick Donnelly - Citi John Sourbeer - UBS Operator Welcome to the QuidelOrtho Fourth Quarter and Full Year 2023 Fi ...

QuidelOrtho Corporation (NASDAQ:QDEL) Q3 2023 Earnings Conference Call November 1, 2023 5:00 PM ET Company Participants Juliet Cunningham - VP, IR Douglas Bryant - President and CEO Joseph Busky - CFO Conference Call Participants Patrick Donnelly - Citi Alex Nowak - Craig-Hallum Jack Meehan - Nephron Research Andrew Cooper - Raymond James John Sourbeer - UBS Operator Welcome to the QuidelOrtho Third Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participant lines are in a list ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-Q ____________________________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the quarterly period ended October 1, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to ...

November 1, 2023 QuidelOrtho 2023 Third Quarter 2023 Financial Results Q QuidelOrtho © 2023. All Rights Reserved. 2 Forward-Looking Statements Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's commercial, reg ...

August 8, 2023 QuidelOrtho Financial Results 2Q 2023 © 2023. All Rights Reserved. 2 Forward-Looking Statements Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include any statements contained herein that are not strictly historical, including, but not limited to, the synergies and other benefits and results of the busines ...